Diabetes

The diabetes/weight loss drug has surged in popularity, and new trials are evaluating it for certain pediatric patients.

There are 2 features of weight loss interventions which are most likely to improve weight loss outcomes—having access to professional health coaches and social support from other users.

The diabetes/weight loss drug is be evaluated in trials for pediatric patients who are at least 10 years of age.

A growing number of adult and pediatric patients are being diagnosed with type 2 diabetes, despite increases in care modalities.

Defective RNA editing in cells in the pancreas may spur the body to initiate an inflammatory attack against its own cells.

Inadequate levels of zinc, vitamin D, vitamin E, and vitamin B were also associated with risk of diabetes or diabetes-related complications.

These patients may have a similar genetic susceptibility for type 2 diabetes.

These patients may have a similar genetic susceptibility for type 2 diabetes, although they have an individual risk for GDM independent of the risk of type 2 diabetes.

This combination regimen, which was compared to once-daily insulin glargine U100 with insulin aspart, had also demonstrated a safe and well-tolerated profile with mild AEs.

Most important of all, we gained a new level of empathy and understanding for patients diagnosed with diabetes whose diagnosis requires that they are constantly mindful and attentive to the balance of diet, exercise, and lifestyle in their day-to-day lives.

Patients who received telemedicine alone had worse glycemic control and less improvement in hemoglobin A1c levels.

Health coaches supporting remote pharmacist services can improve diabetes disparities.

This latest revision introduces a new set of drug criteria, refines the existing ones, and enhances the overall formatting to ensure increased ease of use and clarity for its recommendations.

This month's Pharmacy Times Condition Watch features obesity and type 2 diabetes.

Cole Daniels, PharmD, BCPS, discusses a quality improvement initiative for glycemic outcomes with pharmacist management of insulin.

Jennifer N. Clements PharmD, BCACP, BC-ADM, BCPS, CDCES, FADCES, FCCP discusses the role of Semaglutide and Tirzepatide for type 2 diabetes and obesity

A new hydrogel drug delivery system could change the way diabetes is managed.

Tirzepatide is already approved under the brand name Mounjaro (Lilly) to be used along with diet and exercise to improve blood sugar in adults with type 2 diabetes.

Pricing is also a key issue, as many insurance plans do not cover these medications’ use for obesity.

Investigators found that there was no association of dementia incidence in insulin use at 5 years after stopping metformin and an association at 0.07 years for HbA1C level at year 1.

A low carbohydrate diet plus a sodium glucose contransporter-2 (SGLT2) inhibitor was found to be safe and effective for weight loss and glycemic control in patients with diabetes and chronic kidney disease.

Although SGLT2 inhibitors are not a cure of diabetic kidney disease, this treatment can help reduce the risk and manage the disease either alone or with complementary therapies.

Sodium-glucose cotransporter-2 inhibitors and sodium zirconium cyclosilicate may be paired with these kidney disease medications to reduce high serum potassium.

Coca notes the importance of precision medicine in CKD risk assessment and describes the potential impact multiple therapies can have on future CKD prediction and treatment in the future.